Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued...
Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....
Read more about OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...
Read more about OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...
CHICAGO--(BUSINESS WIRE)--June 5, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company's lead product, Tarceva®, presented...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding...
Arginine vasopressin (AVP) receptor antagonist now approved for the management of the two most common forms of potentially life-threatening sodium/water imbalance DEERFIELD, Illinois, March 2,...
Read more about FDA Approves Astellas' Vaprisol® for the Treatment of Hypervolemic Hyponatremia
Multi-award winning program offers resources to empower transplant patients and their caregivers DEERFIELD, IL, February 26, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Follow U.S. news
